Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors

JCO Precis Oncol. 2023 May:7:e2200697. doi: 10.1200/PO.22.00697.

Monica F Chen^{1

2}, Soo-Ryum Yang³, Jinru Shia³, Jeffrey Girshman⁴, Sippy Punn⁵, Clare Wilhelm¹, Mark G Kris¹, Emiliano Cocco⁶, Alexander Drilon^{1

2}, Nitya Raj⁵

¹ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY.
² Early Drug Development Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.
³ Department of Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.
⁴ Department of Radiology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.
⁵ Gastrointestinal Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.
⁶ Department of Biochemistry and Molecular Biology/Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL.

No abstract available

Publication types